A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), and Nevirapine (NVP) as GPO-Vir Z30 Pediatric Tablets Versus the Individual Liquid Formulations in HIV-Infected Children Greater Than or Equal to Five Months and Less Than 13 Years of Age in Thailand
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 4
- 主要终点
- Safety and comparative bioavailability measured by concentration difference between the GPO-Vir Z30 and standard liquid regimens
研究概览
简要总结
In 2005, there were 50,620 HIV-infected children living in Thailand. Current anti-HIV regimens, comprised of individual pills for each drug, frequently lead to missed doses. To properly control their infection, regimens that are tolerable and effective in children and without pill burden are necessary. The primary purpose of this study is to evaluate the safety and bioavailability of GPO-VIR Z30, a combination fixed dose tablet containing zidovudine (ZDV), lamivudine (3TC), and nevirapine (NVP), in HIV-infected children in Thailand.
详细描述
An important factor affecting the therapeutic response to ARVs is adherence. A common reason for poor adherence is high pill burden. A combination fixed dose drug approach appears to be an effective strategy to improve adherence and therapeutic response. In this study, investigators will compare the bioavailability and safety of GPO-VIR Z30, a combination fixed dose drug, with the liquid formulations of ZDV,3TC, and NVP, in children.
This study will last approximately 8 weeks. Participants will be randomly assigned to one of two arms. Participants in Arm 1 will receive GPO-VIR Z30 for 2 weeks before receiving liquid formulations of ZDV, 3TC, and NVP for the following 2 weeks. Participants in Arm 2 will receive liquid formulations of ZDV, 3TC, and NVP for 2 weeks before receiving GPO-VIR Z30 for the following 2 weeks.
This study will consist of 4 study visits after screening. Visits will occur at study entry and on Days 14, 28, and 56. Medical history and a physical exam will occur at all visits. A pregnancy test will occur for females at all visits. Pharmacokinetic tests, involving hospitalization for the 12 hour procedure, will occur on Days 14 and 28. Safety and adherence monitoring will occur by telephone on Days 7, 11 or 12, 13, 21, 25 or 26, 27, and 35. Home visits for directly observed therapy (DOT) may also occur.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 5 Months 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Weigh between 6 and 30 kilograms
- •HIV infected
- •Receiving HAART regimen of NVP and 2 NRTIs. More information on this criterion can be found in the protocol.
- •Agree to use two appropriate forms of contraception. More information on this criterion can be found in the protocol.
- •Ability to swallow study drugs
- •Willing to be hospitalized for 12-hour intensive PK study
- •Agree to use two appropriate forms of contraception. More information on this criterion can be found in the protocol.
- •Parent or legal guardian able and willing to provide written informed consent
排除标准
- •Certain abnormal laboratory values. More information on this criterion can be found in the protocol.
- •Vomiting or diarrhea (greater than Grade 2) within 30 days prior to study entry
- •History of immunologic failure. More information on this criterion can be found in the protocol.
- •Current treatment for an acute serious bacterial, viral, or opportunistic infection
- •History of dose-limiting toxicity requiring treatment discontinuation of any of the study drugs
- •Hypersensitivity to study drugs
- •Surgical or medical problem affecting gastrointestinal motility or absorption or liver function
- •Treatment with experimental drugs within 30 days prior to study entry
- •Acute hepatitis
- •Chemotherapy for active malignancy
- •Any clinically significant diseases or findings during the screening medical history or physical examination that, in the opinion of the investigator, may interfere with the study
研究组 & 干预措施
1
Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
干预措施: GPO-Vir Z30 tablet (Drug)
1
Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
干预措施: Lamivudine (Drug)
1
Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
干预措施: Nevirapine (Drug)
1
Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
干预措施: Zidovudine (Drug)
2
Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.
干预措施: GPO-Vir Z30 tablet (Drug)
2
Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.
干预措施: Lamivudine (Drug)
2
Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.
干预措施: Nevirapine (Drug)
2
Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.
干预措施: Zidovudine (Drug)
结局指标
主要结局
Safety and comparative bioavailability measured by concentration difference between the GPO-Vir Z30 and standard liquid regimens
时间窗: Throughout study
Therapeutic adequacy of NVP measured by treatment-specific concentration distributions
时间窗: Throughout study
次要结局
- Comparisons in PK analyses between GPO-VIR Z30 and standard liquid regimens including pharmacokinetic parameters, adverse drug reactions, and the influence of SNPs on NVP pharmacokinetic parameters(Throughout study)